Is FOLFOX-HAIC superior to transarterial chemoembolization in treating large hepatocellular carcinoma?
作者信息
Cai Yun-Shi, Wu Hong
机构信息
Department of Liver Surgery & Liver Transplantation, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, China.
出版信息
Hepatobiliary Surg Nutr. 2022 Feb;11(1):164-165. doi: 10.21037/hbsn-21-503.
Abstract
摘要
相似文献
1
Is FOLFOX-HAIC superior to transarterial chemoembolization in treating large hepatocellular carcinoma?在治疗大肝癌方面，FOLFOX-HAIC是否优于经动脉化疗栓塞术？
Hepatobiliary Surg Nutr. 2022 Feb;11(1):164-165. doi: 10.21037/hbsn-21-503.
2
Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.使用改良FOLFOX方案的肝动脉灌注化疗与经动脉化疗栓塞术治疗巨大不可切除肝细胞癌的前瞻性非随机研究。
Chin J Cancer. 2017 Oct 23;36(1):83. doi: 10.1186/s40880-017-0251-2.
3
Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma.经肝动脉化疗栓塞术联合肝动脉灌注化疗加 S-1 治疗肝细胞癌。
World J Gastroenterol. 2020 Jul 21;26(27):3975-3988. doi: 10.3748/wjg.v26.i27.3975.
4
Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization.肝动脉灌注化疗改良 FOLFOX 方案作为经动脉化疗栓塞失败或不适合患者的晚期肝细胞癌的替代治疗选择。
Acad Radiol. 2021 Nov;28 Suppl 1:S157-S166. doi: 10.1016/j.acra.2021.01.024. Epub 2021 Feb 27.
5
A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.使用阿霉素进行高剂量肝动脉灌注化疗与经动脉化疗栓塞治疗难治性晚期肝细胞癌的对比研究。
Korean J Hepatol. 2010 Dec;16(4):355-61. doi: 10.3350/kjhep.2010.16.4.355.
6
Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.奥沙利铂联合氟尿嘧啶肝动脉灌注化疗与经肝动脉化疗栓塞/栓塞治疗合并主门静脉癌栓的中晚期肝癌的疗效比较
Cardiovasc Intervent Radiol. 2020 Jul;43(7):996-1005. doi: 10.1007/s00270-019-02406-3. Epub 2020 Jan 23.
7
Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization?肝动脉灌注化疗对经动脉化疗栓塞耐药的晚期肝细胞癌是否有效治疗？
World J Gastroenterol. 2012 Apr 28;18(16):1933-9. doi: 10.3748/wjg.v18.i16.1933.
8
Effect of double platinum agents, combination of miriplatin-transarterial oily chemoembolization and cisplatin-hepatic arterial infusion chemotherapy, in patients with hepatocellular carcinoma: Report of two cases.双铂类药物（米铂经动脉油性化疗栓塞与顺铂肝动脉灌注化疗联合应用）对肝细胞癌患者的疗效：2例报告
World J Clin Cases. 2017 Jun 16;5(6):238-246. doi: 10.12998/wjcc.v5.i6.238.
9
Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.经动脉化疗栓塞术联合仑伐替尼对比经动脉化疗栓塞术联合索拉非尼作为伴门静脉癌栓的肝细胞癌一线治疗的前瞻性随机研究。
Cancer. 2021 Oct 15;127(20):3782-3793. doi: 10.1002/cncr.33677. Epub 2021 Jul 8.
10
Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study.经动脉化疗栓塞术治疗直径超过10厘米的巨大肝细胞癌：一项大型队列研究
Med Oncol. 2015 Mar;32(3):64. doi: 10.1007/s12032-015-0504-3. Epub 2015 Feb 15.
引用本文的文献
1
Efficacy of hepatic arterial infusion chemotherapy in patients with primary liver cancer with portal vein tumor thrombosis: a comparative analysis of different perfusion chemotherapeutic regimens.肝癌合并门静脉癌栓患者行肝动脉灌注化疗的疗效：不同灌注化疗方案的对比分析。
Eur J Med Res. 2024 Sep 19;29(1):465. doi: 10.1186/s40001-024-02053-6.
2
Development and validation of a nomogram to predict cancer-specific survival of patients with large hepatocellular carcinoma accepting surgical resection: a real-world analysis based on the SEER database.预测接受手术切除的大肝细胞癌患者癌症特异性生存的列线图的开发与验证：基于监测、流行病学和最终结果（SEER）数据库的真实世界分析
J Gastrointest Oncol. 2024 Aug 31;15(4):1657-1673. doi: 10.21037/jgo-24-285. Epub 2024 Aug 20.
3
Comparative effectiveness of interventional therapeutic modalities for unresectable hepatocellular carcinoma: A systematic review and network meta-analysis.不可切除肝细胞癌介入治疗方式的比较有效性：一项系统评价和网状Meta分析。
Oncol Lett. 2022 Aug 31;24(4):366. doi: 10.3892/ol.2022.13486. eCollection 2022 Oct.
本文引用的文献
1
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.奥沙利铂、氟尿嘧啶和亚叶酸钙肝动脉灌注与经动脉化疗栓塞治疗大肝细胞癌的随机III期试验
J Clin Oncol. 2022 Jan 10;40(2):150-160. doi: 10.1200/JCO.21.00608. Epub 2021 Oct 14.
2
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).肝细胞癌诊疗指南（2019年版）
Liver Cancer. 2020 Dec;9(6):682-720. doi: 10.1159/000509424. Epub 2020 Nov 11.
3
Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.死亡率、发病率和风险因素在中国及其省份，1990-2017 年：2017 年全球疾病负担研究的系统分析。
Lancet. 2019 Sep 28;394(10204):1145-1158. doi: 10.1016/S0140-6736(19)30427-1. Epub 2019 Jun 24.
4
Cancer incidence and mortality in China, 2014.2014年中国的癌症发病率和死亡率
Chin J Cancer Res. 2018 Feb;30(1):1-12. doi: 10.21147/j.issn.1000-9604.2018.01.01.
5
Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.异常凝血酶原（PIVKA-II）在早期肝细胞癌诊断和微血管侵犯预测中的性能。
J Hepatol. 2015 Apr;62(4):848-54. doi: 10.1016/j.jhep.2014.11.005. Epub 2014 Nov 11.
6
Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma.双重生物标志物甲胎蛋白（AFP）和异常凝血酶原（PIVKA-II）在局部晚期肝细胞癌预后分组中的临床应用价值
Liver Int. 2014 Feb;34(2):313-21. doi: 10.1111/liv.12274. Epub 2013 Jul 29.
Zotero 插件